Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Replicor Inc. · Hepatitis B, Chronic
Phase 1 / Phase 2
Completed
12
2016-01
Industry sponsor intelligence
Replicor Inc.Clinical Pipeline.
Lead-sponsor view of Replicor Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 12
Pipeline overview
Programs by phase and activity.
Velocity
Replicor Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 11
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Thymosin Alpha-1 → | 1 | 1 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Replicor Inc. studies.
This page groups studies where Replicor Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates